@article {HEERS6437, author = {HENDRIK HEERS and PATRICK DE GEETER and PETER J. GOEBELL and ULLRICH MATZ and WITO DE SCHULTZ and BIRGIT EDLICH and MARGITTA RETZ and AXEL HEGELE}, title = {Vinflunine in the Treatment of Upper Tract Urothelial Carcinoma {\textendash} Subgroup Analysis of an Observational Study}, volume = {37}, number = {11}, pages = {6437--6442}, year = {2017}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: Despite an expected prognostic disadvantage for upper tract versus lower tract metastatic urothelial carcinomas (UTUC/LTUC), only few studies have been conducted to elucidate potential differences in chemotherapy treatment. Patients and Methods: A post-hoc subgroup analysis of a non-interventional study investigating vinflunine after failure of a platinum-based chemotherapy in metastatic/locally advanced UC patients was performed. Results: A total of 18 and 59 out of 77 patients had UTUC and LTUC, respectively. The effectiveness of vinflunine treatment was comparable with an overall response rate of 22.2\% and 23.7\% respectively and a median progression-free survival of 2.76 months in both groups. Median overall survival was 5.0 months in UTUC compared to 8.2 months in the LTUC group (p=0.478). The safety profile was in accordance with previous vinflunine experiences, with a comparable frequency of adverse events in both groups. Conclusion: Vinflunine can be applied in the 2nd line for UC regardless of the primary tumor localization.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/37/11/6437}, eprint = {https://ar.iiarjournals.org/content/37/11/6437.full.pdf}, journal = {Anticancer Research} }